Endocrinology
Hyperprolactinaemia / Prolactinoma
Confirm true hyperprolactinaemia, exclude drug/secondary, MRI, dopamine agonist (cabergoline) first-line.
Source: Endocrine Society 2011
Step 1 of ~3
info
Recognise + Confirm
Features: galactorrhoea (women > men), oligo/amenorrhoea, infertility, ↓ libido / ED (men), gynaecomastia, headache + visual field defects (macroprolactinoma).
• Confirm with paired prolactin (rest 30 min before). Macroprolactin (high MW complex — biologically inactive) — request macroprolactin assay if asymptomatic + raised total prolactin.
• Hook effect: very high prolactin can paradoxically read as low — repeat with 1:100 dilution if macroadenoma + 'normal' prolactin.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Cabergoline (Hyperprolactinaemia / OHSS Prevention) · Dopamine Agonist — Hyperprolactinaemia / OHSS
- Cabergoline · Dopamine Agonist (D2 Receptor) / Prolactin Inhibitor
- Bromocriptine (Hyperprolactinaemia) · Dopamine Agonist — Hyperprolactinaemia
- Phenylephrine · Alpha-1 Adrenergic Agonist (Pure Vasoconstrictor)
- Bromocriptine · Dopamine Agonist (D2 Receptor) / Prolactin Inhibitor
- Quinagolide · Selective D2 dopamine agonist (non-ergot)
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only. Always apply local guidelines and clinical judgement.